- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Non-Hodgkin’s lymphoma (also known as NHL, or sometimes just lymphoma) is a type of cancer that starts in the lymphatic system, in white blood cells called lymphocytes that are part of the body’s immune system. NHL is a term used for many different types of lymphoma, all of which share some of the same characteristics.
Showing all 12 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
CD20 |
Biosimilar , Monoclonal Antibody |
Ruxience® |
10 mg/mL |
– |
2 mg |
tba |
tba |
196,00 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Truxima® |
10 mg/mL |
– |
2 mg |
tba |
tba |
234,00 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.05 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.09 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.12 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.02 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.02 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.08 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.12 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2021.07 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
4 mg |
-80°C |
2026.04 |
196,00 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Rixathon® |
10 mg/mL |
– |
2 mg |
-80 °C |
2026.03 |
311,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany